Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1120

1.

Optimal dosing of subcutaneous unfractionated heparin for the treatment of deep vein thrombosis.

Kearon C, Harrison L, Crowther M, Ginsberg JS.

Thromb Res. 2000 Mar 15;97(6):395-403.

PMID:
10704648
[PubMed - indexed for MEDLINE]
2.

A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.

Horbach T, Wolf H, Michaelis HC, Wagner W, Hoffmann A, Schmidt A, Beck H.

Thromb Haemost. 1996 Feb;75(2):246-50.

PMID:
8815569
[PubMed - indexed for MEDLINE]
3.

Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times.

Anand SS, Bates S, Ginsberg JS, Levine M, Buller H, Prins M, Haley S, Kearon C, Hirsh J, Gent M.

Arch Intern Med. 1999 Sep 27;159(17):2029-32.

PMID:
10510988
[PubMed - indexed for MEDLINE]
4.

Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis.

Prandoni P, Bagatella P, Bernardi E, Girolami B, Rossi L, Scarano L, Marchiori A, Piccioli A, Girolami A.

Ann Intern Med. 1998 Aug 15;129(4):299-302.

PMID:
9729183
[PubMed - indexed for MEDLINE]
5.

Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.

Kearon C.

Curr Opin Pulm Med. 2007 Sep;13(5):398-402. Review.

PMID:
17940484
[PubMed - indexed for MEDLINE]
6.

Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolism.

Bernardi E, Prandoni P.

Curr Opin Pulm Med. 2005 Sep;11(5):363-7. Review.

PMID:
16093806
[PubMed - indexed for MEDLINE]
7.

Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.

Harenberg J, Schmidt JA, Koppenhagen K, Tolle A, Huisman MV, Büller HR.

Thromb Haemost. 2000 May;83(5):652-6.

PMID:
10823256
[PubMed - indexed for MEDLINE]
8.

Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis.

Hylek EM, Regan S, Henault LE, Gardner M, Chan AT, Singer DE, Barry MJ.

Arch Intern Med. 2003 Mar 10;163(5):621-7.

PMID:
12622610
[PubMed - indexed for MEDLINE]
9.

Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.

Harenberg J, Stehle G, Blauth M, Huck K, Mall K, Heene DL.

Semin Thromb Hemost. 1997;23(1):83-90.

PMID:
9156415
[PubMed - indexed for MEDLINE]
10.

Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis.

Hirsch DR, Lee TH, Morrison RB, Carlson W, Goldhaber SZ.

Am Heart J. 1996 Feb;131(2):276-80.

PMID:
8579021
[PubMed - indexed for MEDLINE]
11.

Current management of acute symptomatic deep vein thrombosis.

Heit JA.

Am J Cardiovasc Drugs. 2001;1(1):45-50. Review.

PMID:
14728051
[PubMed - indexed for MEDLINE]
12.

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.

Merli G, Spiro TE, Olsson CG, Abildgaard U, Davidson BL, Eldor A, Elias D, Grigg A, Musset D, Rodgers GM, Trowbridge AA, Yusen RD, Zawilska K; Enoxaparin Clinical Trial Group.

Ann Intern Med. 2001 Feb 6;134(3):191-202.

PMID:
11177331
[PubMed - indexed for MEDLINE]
13.

Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis.

Fiessinger JN, Lopez-Fernandez M, Gatterer E, Granqvist S, Kher A, Olsson CG, Söderberg K.

Thromb Haemost. 1996 Aug;76(2):195-9.

PMID:
8865530
[PubMed - indexed for MEDLINE]
14.

Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis.

Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA.

Arch Intern Med. 1997 Dec 8-22;157(22):2562-8.

PMID:
9531224
[PubMed - indexed for MEDLINE]
15.

Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes.

Mungall D, Lord M, Cason S, Treadwell P, Williams D, Tedrick D.

Am J Cardiol. 1998 Sep 1;82(5):574-9.

PMID:
9732882
[PubMed - indexed for MEDLINE]
16.

Comparing subcutaneous danaparoid with intravenous unfractionated heparin for the treatment of venous thromboembolism. A randomized controlled trial.

de Valk HW, Banga JD, Wester JW, Brouwer CB, van Hessen MW, Meuwissen OJ, Hart HC, Sixma JJ, Nieuwenhuis HK.

Ann Intern Med. 1995 Jul 1;123(1):1-9.

PMID:
7539233
[PubMed - indexed for MEDLINE]
17.

Effect of warfarin on activated partial thromboplastin time in patients receiving heparin.

Kearon C, Johnston M, Moffat K, McGinnis J, Ginsberg JS.

Arch Intern Med. 1998 May 25;158(10):1140-3.

PMID:
9605787
[PubMed - indexed for MEDLINE]
18.

A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.

Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M.

Arch Intern Med. 1994 Jan 10;154(1):49-56.

PMID:
8267489
[PubMed - indexed for MEDLINE]
19.

Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism.

Prandoni P, Carnovali M, Marchiori A; Galilei Investigators.

Arch Intern Med. 2004 May 24;164(10):1077-83.

PMID:
15159264
[PubMed - indexed for MEDLINE]
20.

Heparin and low-molecular-weight heparin in the treatment of venous thromboembolism.

Pineo GF, Hull RD.

Baillieres Clin Haematol. 1998 Sep;11(3):621-37. Review.

PMID:
10331096
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk